Biotech News
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
investors.zurabio.com2026-05-07 11:32 EST
Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an